- Home
- CIEN vs CORT Comparison
CIEN vs CORT Comparison
Compare CIEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIEN
- CORT
- Stock Information
- Founded
- CIEN 1992
- CORT 1998
- Country
- CIEN United States
- CORT United States
- Employees
- CIEN N/A
- CORT N/A
- Industry
- CIEN Telecommunications Equipment
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CIEN Utilities
- CORT Health Care
- Exchange
- CIEN Nasdaq
- CORT Nasdaq
- Market Cap
- CIEN 10.2B
- CORT 7.5B
- IPO Year
- CIEN 1997
- CORT N/A
- Fundamental
- Price
- CIEN $81.47
- CORT $73.22
- Analyst Decision
- CIEN Buy
- CORT Strong Buy
- Analyst Count
- CIEN 13
- CORT 4
- Target Price
- CIEN $82.85
- CORT $142.00
- AVG Volume (30 Days)
- CIEN 3.0M
- CORT 1.9M
- Earning Date
- CIEN 06-05-2025
- CORT 07-28-2025
- Dividend Yield
- CIEN N/A
- CORT N/A
- EPS Growth
- CIEN N/A
- CORT 8.36
- EPS
- CIEN 0.73
- CORT 1.14
- Revenue
- CIEN $4,264,558,000.00
- CORT $685,446,000.00
- Revenue This Year
- CIEN $16.34
- CORT $35.83
- Revenue Next Year
- CIEN $9.74
- CORT $35.24
- P/E Ratio
- CIEN $112.00
- CORT $64.14
- Revenue Growth
- CIEN 2.86
- CORT 30.93
- 52 Week Low
- CIEN $44.89
- CORT $29.42
- 52 Week High
- CIEN $101.44
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CIEN 65.52
- CORT 51.47
- Support Level
- CIEN $73.55
- CORT $72.48
- Resistance Level
- CIEN $82.45
- CORT $77.42
- Average True Range (ATR)
- CIEN 2.20
- CORT 2.61
- MACD
- CIEN 0.68
- CORT 0.27
- Stochastic Oscillator
- CIEN 97.07
- CORT 47.96
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.